Amiodarone Drug Interactions: Complete FDA-Sourced Safety Guide

A 67-year-old patient with persistent atrial fibrillation had been stable on amiodarone for three years. When her physician prescribed a newer antiviral medication to treat a respiratory infection, neither she nor her pharmacist immediately flagged a critical interaction. Within 48 hours, she experienced palpitations and dizziness—warning signs of a dangerous cardiac rhythm disturbance. Her case underscores a hard truth: amiodarone is one of the most complex drugs in clinical practice, and its interactions can be life-threatening.

Amiodarone is a potent Class III antiarrhythmic agent used to treat serious heart rhythm disorders, including atrial fibrillation, ventricular tachycardia, and other arrhythmias. While it is highly effective, amiodarone has an extensive interaction profile that demands careful monitoring. According to FDA drug labeling data in our database of over 250,000 FDA-labeled drug records, amiodarone has numerous contraindicated and major interactions that can lead to life-threatening cardiac events.

What is Amiodarone Used For?

Amiodarone works by slowing electrical conduction in the heart and prolonging the refractory period—the time during which heart tissue cannot be stimulated to contract again. This makes it especially useful for patients with dangerous arrhythmias that do not respond to other medications. However, this same mechanism that makes amiodarone effective also makes it susceptible to dangerous interactions with drugs that similarly affect cardiac conduction or that increase amiodarone's concentration in the bloodstream.

Contraindicated Interactions: Drugs You Must Avoid With Amiodarone

According to FDA drug labeling, contraindicated interactions mean the combination should be avoided entirely. The risk of harm outweighs any potential benefit. Here are the critical contraindicated combinations documented in our FDA database:

• Nirmatrelvir and ritonavir (Paxlovid): This widely used COVID-19 antiviral combination is a potent CYP3A inhibitor. Co-administration with amiodarone can dramatically increase amiodarone plasma concentrations, raising the risk of serious cardiac arrhythmias. The FDA label explicitly recommends avoiding this combination.
• Sotalol hydrochloride: Both amiodarone and sotalol are Class III antiarrhythmics that prolong the cardiac refractory period. Using them together creates additive effects on cardiac conduction and dramatically increases the risk of torsade de pointes—a life-threatening form of ventricular tachycardia. The FDA labels state this combination is not recommended.
• Propafenone hydrochloride: Propafenone is a Class IC antiarrhythmic. Combined with amiodarone's Class III effects, this pairing leads to unpredictable effects on cardiac conduction and repolarization. FDA labeling documents state concomitant administration is not recommended.
• Macimorelin acetate: This growth hormone secretagogue can prolong the QT interval. When combined with amiodarone's own QT-prolonging effects, the risk of torsade de pointes becomes unacceptable. FDA data marks this as contraindicated.
• Macitentan (alone or with tadalafil): Amiodarone is a dual CYP3A4 and CYP2C9 inhibitor that significantly increases macitentan exposure. This combination risks hepatotoxicity and hemodynamic instability. The FDA labels advise avoiding co-administration.

Major Interactions: High-Risk Combinations Requiring Caution

While not absolutely contraindicated, major interactions pose serious risks and require careful clinical judgment, dose adjustment, or monitoring. The following drugs carry major interaction warnings with amiodarone according to FDA labeling:

• Tetrabenazine: This Class III antiarrhythmic prolongs the QTc interval. Concomitant use risks additive QTc prolongation and torsade de pointes. The FDA labels recommend avoiding this combination or using it only under close cardiac monitoring.
• Carvedilol phosphate: Amiodarone inhibits CYP2D6, the enzyme responsible for carvedilol metabolism. This inhibition increases carvedilol plasma concentrations, resulting in further slowing of heart rate and potentially dangerous decreases in cardiac output. Dose adjustment may be necessary.
• Etrasimod: This drug can independently prolong the QT interval. The additive effect with amiodarone's QT-prolonging properties increases the risk of serious arrhythmias. FDA labeling recommends avoiding this combination.
• Anagrelide: Anagrelide can prolong the QT interval and increase arrhythmia risk. Combined with amiodarone, this risk becomes major. FDA labeling advises against concomitant use.

Understanding the Mechanisms: Why These Interactions Matter

Most amiodarone interactions operate through two primary mechanisms:

1. QT Prolongation and Torsade de Pointes: The QT interval is a measure of electrical activity in the heart. When it becomes abnormally prolonged, the heart becomes vulnerable to a chaotic rhythm called torsade de pointes. This rhythm can degenerate into cardiac arrest. Many of amiodarone's dangerous interactions involve drugs that also prolong the QT interval, creating a synergistic effect.

2. CYP Enzyme Inhibition: Amiodarone is a powerful inhibitor of cytochrome P450 enzymes, particularly CYP3A4, CYP2D6, and CYP2C9. These enzymes are responsible for metabolizing hundreds of medications. When amiodarone blocks these enzymes, other drugs accumulate to toxic levels in the bloodstream. This is especially dangerous with drugs that have narrow therapeutic windows or cardiac effects of their own.

FDA Adverse Event Reporting: What the Data Shows

The U.S. FDA's FAERS (Adverse Event Reporting System) database contains thousands of reports linking amiodarone to serious adverse events, particularly when combined with other medications. Common reported outcomes include:

• Torsade de pointes and other ventricular arrhythmias
• Bradycardia (abnormally slow heart rate)
• Cardiac arrest
• Syncope (fainting)
• Hepatotoxicity
• Pulmonary toxicity

These reports underscore that amiodarone interactions are not theoretical—they cause real harm to real patients.

Practical Guidance for Patients Taking Amiodarone

If you are taking amiodarone, follow these critical steps:

• Inform every healthcare provider: Tell your doctor, dentist, pharmacist, and any specialist that you take amiodarone. This includes urgent care centers and emergency departments.
• Use one pharmacy: Consolidating all prescriptions at a single pharmacy helps ensure consistent interaction checking.
• Never add new medications without approval: Even over-the-counter drugs, supplements, and herbal products can interact with amiodarone. Always check first.
• Report new symptoms: Chest pain, palpitations, shortness of breath, dizziness, or fainting warrant immediate medical attention.
• Attend all appointments: Amiodarone requires periodic monitoring with blood tests and heart rhythm assessments.

The Bottom Line

Amiodarone is an invaluable medication for patients with serious arrhythmias, but its interaction profile demands respect and vigilance. The FDA drug labeling data in our database clearly identifies multiple contraindicated and major interactions that can cause life-threatening complications. The responsibility for safety rests on multiple shoulders—your prescriber, your pharmacist, and you—working together to prevent dangerous combinations.

Do not assume your healthcare team has caught every interaction. The complexity of modern medicine means gaps can occur. That is why independent verification is essential.

Use checkdruginteractions.com—the most comprehensive drug interaction checker on the internet—to verify your complete medication list against our database of over 250,000 FDA-labeled drug records. Our tool lets you check up to 20 drugs simultaneously and provides instant, severity-ranked feedback on all interactions, sourced directly from FDA labeling and the National Library of Medicine. No account needed. Check your medications today.